<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-07-08T08:44:08Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/B9E37B2F-E82D-43B0-94EB-2A0E3D5407A1" ns1:id="B9E37B2F-E82D-43B0-94EB-2A0E3D5407A1"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/8FBFBF60-D7B2-45A0-BDAC-EF79F876EB84" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/E8BCC1AD-30C6-4D78-8623-7F63F943E080" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/E8BCC1AD-30C6-4D78-8623-7F63F943E080" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2018-03-30T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/5F634818-3CDC-49F1-AEF8-F89624138853" ns1:rel="FUND" ns1:start="2015-03-31T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">102138</ns2:identifier></ns2:identifiers><ns2:title>Design for manufacture of an innovative Extra Corporeal Membrane Oxygenator</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Respiratory problems cost the NHS over &amp;pound;2,500 million/annum. The project aims to deliver safe effective Extracorporeal Membrane Oxygenation with reduced risk of blood clots that will improve lives and reduce these costs. Current alternatives have a propensity to cause blood clots and consequently require high levels of anticoagulation. This anticoagulation introduces a risk of haemorrhage and striking a balance between thrombosis and haemorrhage restricts use to a small number of expensive specialist centres. The initial focus is on post-operative support for cardiopulmonary patients to improve recovery rates and reduce hospital stays. Future developments foresee application to a wide range of conditions including drug-free treatment for aggressive ‘flu pandemics and, in the longer term, support for people suffering chronic lung diseases. It is anticipated that over 90% of production from facilities in South Wales will be exported.</ns2:abstractText></ns2:project>